Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Brigatinib + Bevacizumab for Lung Cancer
Recruiting1 awardPhase 1
Duarte, California
This trial is testing brigatinib with or without bevacizumab to treat patients with ALK-rearranged non-small cell lung cancer that has spread to nearby tissues or lymph nodes (locally advanced) or other places in the body (metastatic) or has come back (recurrent).
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.